Answering the Call in Nonadvanced Systemic Mastocytosis: Targeted Approaches to Patient Management

Prefer to participate in person? Register for our live program.

Target Audience

The design of this activity addresses the needs of clinical immunologists/allergists, dermatologists, gastroenterologists, hematologists, and other specialist clinicians who diagnose or manage nonadvanced systemic mastocytosis (SM).

Program Overview

Nonadvanced SM is a challenging disorder to diagnose and manage due to the heterogeneity of symptoms, anaphylactic triggers, and complicated therapeutic paradigm. Join us for this unique and engaging Call-a-Colleague program, in which a panel of multidisciplinary faculty will discuss evolving diagnostic and management strategies for nonadvanced SM.

Learning Objectives

After completing this activity, the participant should be better able to:

• Describe key pathophysiologic processes in SM, with a focus on potential clinical manifestations and the rationale for new targeted therapies
• Evaluate patients with suspected nonadvanced SM to characterize symptoms, disease burden, and results from appropriate ancillary testing
• Discuss clinical trial evidence and appropriate use of targeted treatment options for nonadvanced SM
• Individualize treatment regimens for nonadvanced SM to reflect clinical evidence for efficacy and safety, patient-reported outcomes, and shared clinical decision-making

Agenda

Disclosures of Relevant Financial Relationships

All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted to assure objectivity and that the activity is free of commercial bias.

The faculty have the following relevant financial relationships with ineligible companies:

Matthew P. Giannetti, MD: Consulting Fees: Blueprint Medicines, Cogent Biosciences, Inc.; Contracted Research: Blueprint Medicines

Anne L. Maitland, MD: Consulting Fees: Blueprint Medicines, Cogent Biosciences, Inc., TerSera Therapeutics, LLC; Speakers' Bureau: Blueprint Medicines

Matthew J. Hamilton, MD: Consulting Fees: Blueprint Medicines, InveniAI, LLC

Lauren M. Madigan, MD: Consulting Fees: Blueprint Medicines

The planners and managers have reported no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The opinions expressed in the activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this activity.

Americans With Disabilities

Any activity registrant who feels s/he may need accommodation based on the impact of a disability should contact Integritas Communications at info@exchangecme.com to discuss their specific needs.

Contact Information

For information about this program, please contact us at info@exchangecme.com.

The Non-CME Corporate Forum content and views expressed therein do not necessarily reflect the views, policies or position of the American College of Allergy, Asthma & Immunology.